Elastic Cloud Hosted Achieves FedRAMP® High "In Process" Status
Elastic (NYSE: ESTC), the Search AI Company, announced Elastic Cloud Hosted has achieved the Federal Risk and Authorization Management Program (FedRAMP) High 'In Process' status on AWS GovCloud (US). This milestone reinforces Elastic's commitment to delivering secure and compliant solutions that support the U.S. Federal Government in safeguarding controlled unclassified information (CUI) and other sensitive, high-impact data across various mission-critical use cases.
FedRAMP High is the program's most stringent security baseline, requiring more than 400 rigorous security controls to protect cloud environments that manage sensitive unclassified data, including information related to national security, critical infrastructure and financial risk. Elastic Cloud Hosted is already FedRAMP Moderate authorized on AWS GovCloud (US), supporting a wide range of public sector agencies.
'Achieving FedRAMP High 'In Process' status is a significant step toward expanding our support for federal agencies with high-security workloads,' said Chris Townsend, global vice president, Public Sectorat Elastic. 'Whether it's advancing Zero Trust strategies or building generative AI applications, Elastic is committed to delivering secure, transparent, compliant and cost-effective solutions to help government agencies achieve their missions.'
With the 'In Process' designation in place, Elastic is working closely with its sponsoring agency and third-party assessors to complete the final phases of the FedRAMP High authorization process. Upon receiving final authorization, Elastic Cloud Hosted will be cleared to support the government's most security-sensitive workloads in compliance with FedRAMP High.
Additional Materials
About Elastic
Elastic (NYSE: ESTC), the Search AI Company, enables everyone to find the answers they need in real-time using all their data, at scale. Elastic's solutions for search, observability, and security are built on the Elastic Search AI Platform, the development platform used by thousands of companies, including more than 50% of the Fortune 500. Learn more at elastic.co.View source version on businesswire.com:https://www.businesswire.com/news/home/20250708251362/en/
CONTACT: Media Contact
Elastic PR
[email protected]
KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: DATA MANAGEMENT SECURITY TECHNOLOGY SOFTWARE ARTIFICIAL INTELLIGENCE INTERNET
SOURCE: Elastic N.V.
Copyright Business Wire 2025.
PUB: 07/08/2025 12:20 PM/DISC: 07/08/2025 12:20 PM
http://www.businesswire.com/news/home/20250708251362/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
2 Healthcare Stocks That Have Doubled Over the Last Year but Still Have Room to Run
Key Points Hims & Hers Health is unlocking new sources of growth potential, and its balance sheet is flourishing. Doximity is a prime platform for advertisers, and the profits are pouring in. 10 stocks we like better than Hims & Hers Health › It's been a wild first half of the year for stocks in 2025, but finding the right companies for your portfolio is a very personal process. You need to consider the type of stocks you want to buy, the industries and sectors you gravitate toward, the amount of capital you have to invest, and your own personal risk tolerance. If you have cash to invest in the stock market right now, and you're looking for growth stocks that could make smart additions to the basket of businesses you own, there are names to be found across a range of industries, including healthcare. Here are two healthcare stocks that have at least doubled over the past 12 months but still look poised to deliver favorable returns for shareholders in the next three to five years. 1. Hims & Hers Health Hims & Hers Health (NYSE: HIMS) has witnessed a stock run-up of more than 200% over the trailing-12-month period. In contrast, the S&P 500 is up only about 18% in that same time frame. This boom in the company's share price has occurred for a few reasons. Investors were particularly excited about the company's ability to offer affordable, compounded GLP-1 drugs for weight loss amid shortages of branded versions, and that fueled significant revenue growth and share-price appreciation. However, Hims & Hers can no longer mass-produce compounded drugs like semaglutide because the U.S. Food and Drug Administration declared the shortage resolved. While the company may still offer personalized doses where clinically applicable, its primary weight loss offerings are shifting to oral medications and liraglutide. In fact, Novo Nordisk, the maker of Wegovy (semaglutide for weight) and Ozempic (semaglutide for diabetes), ended its partnership with Hims & Hers, citing concerns over the latter company's promotion and sales of compounded semaglutide. While the company's offerings may evolve in the coming months and years, it has other sources of growth to lean on besides the weight loss segment. Hims & Hers' areas of focus include sexual health, hair loss, dermatology, mental health, and primary care. The platform also provides access to both over-the-counter and prescription treatments via online consultations with licensed healthcare professionals, and most of its revenue still comes from recurring subscriptions paid by healthcare consumers. The recent acquisition of Zava, a European digital health platform, seems to have boosted investor confidence in the future of the business outside of its ambitions in the weight loss industry. The addition of Zava to Hims & Hers' ecosystem will expand its reach into the U.K., Ireland, France, and Germany. Hims & Hers also plans to launch its platform in Canada in 2026. Revenue grew by 110% year over year in the first quarter, and the company is building upon an improving track record of profitability. Hims & Hers also delivered free cash flow of about $50 million in Q1. This business has a lot of potential. 2. Doximity Doximity (NYSE: DOCS) has seen shares pop by a bit more than 100% since this time one year ago. Doximity is known as the largest digital platform for U.S. medical professionals. It serves as a professional and social network for healthcare professionals including doctors, nurse practitioners, and physician assistants, and offers a wide variety of tools for communication, news, and career management. Doximity provides a curated newsfeed with the latest medical news and research relevant to different specialties, and also offers tools for job searches, salary comparisons, and reputation management. The platform even provides telehealth solutions, enabling virtual patient visits and consultations. The platform is free for healthcare professionals to use. This free access includes Doximity Dialer, a feature that allows secure communication with patients using a customized calling tool. The platform also offers free digital fax lines and access to Doximity Scribe, an AI-powered note-taking tool for verified clinicians. So, how does Doximity make money? From advertising and selling information. Doximity's platform is a prime digital marketing and advertising tool for pharmaceutical manufacturers and healthcare systems (like hospitals). These entities pay Doximity to advertise and promote their products and services to targeted medical professionals. Health systems and medical recruiting firms also pay Doximity to access its database of medical professionals for recruitment and hiring purposes. In Doximity's fiscal 2025, which ended March 31, revenue increased 20% from the prior fiscal year to $570.4 million. The company reported net income of $223.2 million, up 51% year over year, with free cash flow spiking 50% to $266.7 million. This healthcare stock is really an advertising business at its core, and a profitable one at that. These factors could induce some investors to take another long look at this top stock and I think it has room to run. Do the experts think Hims & Hers Health is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Hims & Hers Health make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,019% vs. just 178% for the S&P — that is beating the market by 841.12%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Rachel Warren has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Doximity and Hims & Hers Health. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 2 Healthcare Stocks That Have Doubled Over the Last Year but Still Have Room to Run was originally published by The Motley Fool 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
Business Upturn
2 hours ago
- Business Upturn
KBR Investor News: If You Have Suffered Losses in KBR, Inc. (NYSE: KBR), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
NEW YORK, Aug. 03, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of KBR, Inc. (NYSE: KBR) resulting from allegations that KBR may have issued materially misleading business information to the investing public. SO WHAT: If you purchased KBR securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses. WHAT TO DO NEXT: To join the prospective class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. WHAT IS THIS ABOUT: On June, 20, 2025, before the market opened, KBR issued a press release entitled 'KBR Announcement on HomeSafe Alliance Global Household Goods Contract.' The press release stated that 'HomeSafe Alliance, a KBR (NYSE: KBR) Joint Venture, informed us on June 18, 2025, that U.S. Transportation Command (TRANSCOM) has terminated HomeSafe's role in the Global Household Goods Contract, a contract designed to improve the moving system for military service members and their families.' On this news, KBR's stock fell $3.85 per share, or 7.2%, to close at $48.93 per share on June 20, 2025. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. ——————————- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected]
Yahoo
2 hours ago
- Yahoo
Better Artificial Intelligence Stock: BigBear.ai vs. Nvidia
Key Points has become an AI investor darling over the past few years. Nvidia is the leading artificial intelligence semiconductor company. There's no substitute for high revenue growth and profitability -- and Nvidia has both. 10 stocks we like better than Nvidia › Many investors are focused on artificial intelligence stocks these days, which can be a smart play as AI transforms many industries. But it's starting to seem like any AI stock is a winner in the market right now, which means some investors may not be doing their due diligence when evaluating companies. With that in mind, two AI companies with surging share prices right now are Nvidia (NASDAQ: NVDA) and (NYSE: BBAI), and it may be worth taking a closer look at both to see which one looks like the better AI stock to buy right now. What's happening with Nvidia Nvidia gets top billing in this matchup because the company has experienced monster growth over the past few years as companies clamor for its artificial intelligence semiconductors. An estimated 70% to 95% of data centers utilize Nvidia's AI processors, and there seems to be no slowing down for the company's growth. For example, Nvidia's total sales soared 114% in fiscal 2025 to $130.5 billion, and its earnings skyrocketed 147% to $2.94 per share. This growth has been fueled by the company's data center segment, which experienced a 142% revenue surge to $115 billion last year. The impressive earnings and revenue growth have resulted in Nvidia's stock surging 57% over the past year. That's pushed the company's valuation higher, and Nvidia's shares currently have a price-to-earnings multiple of about 56. That's not cheap, but it's still lower than the average P/E ratio of 64 in the semiconductor industry right now. What's more, Nvidia could continue to benefit from AI investments for many more years to come. Nvidia CEO Jensen Huang believes AI will fuel $2 trillion in data center spending over the next several years. While Nvidia's growth isn't guaranteed, many tech giants have already committed to spending hundreds of billions of dollars to expand their AI data centers over the next few years. That's creating an ongoing opportunity for Nvidia to continue increasing its sales. What's happening with is an AI data analytics company that helps companies and the U.S. government sort through their data to make decisions. AI analytics is a burgeoning AI trend, and it has propelled the stock of similar companies, like Palantir, into the stratosphere. stock, for its part, has jumped 323% over the past year. But despite its impressive gains, there are some significant concerns I have with including its lack of strong revenue growth. sales increased just 5% in Q1 to $34.8 million, and management's outlook for the full year is for $160 million to $180 million -- an increase of just 7.5% at the midpoint. These are fairly unimpressive sales figures for a small AI company that's trying to tap into an expanding artificial intelligence analytics market. One of the company's problems is that 52% of its revenue comes from just four customers. That's a high concentration of sales from just a handful of customers, and it means that if one or two leave, could be in trouble. And then there's the company's lack of earnings. reported a loss of $1.10 per share last year and continued that trend with a loss of $0.25 per share in Q1. While many small start-ups often aren't profitable, it's problematic that the company's lack of earnings comes in addition to unimpressive sales growth. Meanwhile, stock has a price-to-sales ratio of 11, which is substantially higher than the average P/S multiple of 3 for the S&P 500 and means that investors are paying a premium for it right now. Verdict: Nvidia is the hands-down winner Nvidia's stock isn't cheap, and there are always risks with investing in AI stocks that have already experienced astronomical growth. But the company is a hands-down better investment than because it's massively profitable, continually expanding its revenue, and outpaces its rivals in the AI semiconductor market. Meanwhile, stock is overvalued, its revenue growth is unimpressive, and the company isn't profitable. This makes Nvidia the no-brainer in this matchup and one of the best AI stocks to buy and hold for the long term. Should you buy stock in Nvidia right now? Before you buy stock in Nvidia, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Chris Neiger has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Nvidia and Palantir Technologies. The Motley Fool has a disclosure policy. Better Artificial Intelligence Stock: vs. Nvidia was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
